AVON-BY-THE-SEA, N.J., Oct. 8, 2026 /PRNewswire/ — Vinci Pharmaceuticals Inc., a specialty ophthalmic pharmaceutical company, has closed an $8+ million Series A financing round as the company advances development of its innovative EPIPLANT™ delivery platform. Previously, the company raised $8.5M, excluding interest on convertible notes, in Seed Stage financing, for a total of more than $16.5M.

Developed in the laboratory of Karl Csaky, MD, PhD, and licensed from the Retina Foundation of the Southwest in Dallas, Texas, EPIPLANT™ is a proprietary episcleral implant platform designed to provide sustained drug delivery to retinal tissues and address limitations associated with intraocular injections. Vinci is advancing the program with guidance from its scientific advisory board of physicians.

The financing was led by Dynagrow Capital, LLLP, with support from MintPharma Capital. Proceeds from the financing are expected to support GMP manufacturing, testing and release activities of the EPIPLANT™ VCI-002 product, and the Phase 1/2a study in 2027.

“We are grateful for the support and confidence of our investors and board, who recognize the potential of our EPIPLANT™ delivery system to transform the treatment of sight-threatening diseases and address unmet needs in the field,” said Philip A. Gioia, Co-founder, Chairman and Chief Executive Officer of Vinci Pharmaceuticals. “This financing supports an important next step: preparing for our first-in-human study. We believe EPIPLANT™ has the potential to provide safe sustained drug delivery to retinal tissues and reduce treatment burden for patients and physicians.”

Sarah Hassan, Managing Director at Dynagrow Capital added, “Vinci’s EPIPLANT represents a potential paradigm shift for eye doctors and their patients facing retinal disease challenges. This potential multi-molecule platform technology involving a needle-free delivery system for small molecules could dramatically increase adherence time for patients presently experiencing an unacceptably high dropout rate due to treatment burden. We are happy to partner with Vinci’s talented team and support them in this most pivotal time advancing EPIPLANTVCI-002 to patients.”

The company has been granted multiple patents covering its proprietary EPIPLANT™ technology and has completed preliminary preclinical testing. Vinci plans to initiate a first-in-human Phase 1/2a clinical study in 2027.

Existing drug delivery approaches for retinal diseases often require administration directly into the eye or face challenges in achieving effective drug concentrations in retinal tissues. EPIPLANT™ is designed to address these limitations through sustained drug delivery from an episcleral implant. The bioerodible platform is designed to accommodate a range of active pharmaceutical ingredients, with the potential to support multiple therapies for retinal diseases.

“EPIPLANT™ delivers targeted drug levels to the macula, making it a more desirable option for treating certain ophthalmic diseases of the retina compared to intravitreal injections, the current standard of care,” said Richard Lindstrom, MD, of Minnesota Eye Consultants. “The EPIPLANT™ technology also opens the door to novel therapies for retinal indications that are currently untreated.”

Vinci Pharmaceuticals plans one Phase 1/2a clinical trial of its EPIPLANT™ episcleral sustained-release delivery system in 2027. Currently the system can deliver small molecules, allowing for broad application for multiple retinal diseases.

About Vinci Pharmaceuticals
Vinci Pharmaceuticals Inc. is a clinic ready ophthalmic company that is leveraging a novel, proprietary platform to develop first-, best- and only-in-class products with differentiated profiles to treat certain diseases of the retina.

Safe Harbor
This press release contains forward-looking statements, which include information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulations. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.  Forward-looking statements are based on information Vinci Pharmaceuticals has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Contact
Vinci Pharmaceuticals Inc.
Phil Gioia
Co-Founder, Chairman & CEO
Email: philip.gioia@vincipharmaceuticals.com

NEW YORK, Oct. 8, 2026 — Vocca announced a $20M Series A led by Norrsken VC, with participation from Heal Capital, Speedinvest and Firstminute Capital. Total funding is $25 million.

Vocca’s first product is an AI phone assistant that automates patient calls. A year ago, 2,000 medical practitioners used it. Today 15,000 do, across 1,500 practices and twenty specialties in the US and Europe. Over the same period, conversation volume grew 10x, to more than one million a month, and revenue grew 7x.

On average, Vocca resolves 70% of conversations end-to-end with no human involvement; its most mature customers exceed 85%. National groups run their scheduling on it, DAG Dental (37 practices) for instance, as do hospital systems such as the Hôpital Fondation de Rothschild, which handles intake, calls and confirmations with Vocca for its 350,000 yearly patients.

AI built for how medical practices actually work

Four in ten calls to a medical practice go unanswered, and nearly half of health workers report frequent burnout. Vocca learned each specialty’s scheduling logic, integrated with the software practices already use, and was built to handle patient data securely. Behind the voice is a scheduling engine with a library of specialty-specific models, so practices go live in days rather than months.

The second wave of healthcare AI is conversational

A quarter of US health spending still goes to administration, much of it on the phone. The first wave of AI in medicine was documentation; within a few years, ambient scribes became standard. The second wave is conversational, and it moves faster because it asks no one to change how they work: patients keep calling, staff keep their tools, and what changes is capacity.

Vocca will use the funding to build the best scheduling infrastructure in healthcare and the best interface for patients to reach it: new channels beyond voice, more specialties, and a deeper presence in the United States.

Find out more : https://vocca.com/en/resources/blog/vocca-raises-20m-series-a-led-by-norrsken-vc

About Vocca

Founded in July 2024 by Eliott Hoffenberg and Hugo Danet. Vocca employs around 40 people in New York and Paris and is hiring 40 more by the end of the year.

Press contact: [email protected]

About Norrsken VC

Norrsken VC is Europe’s leading early-stage impact fund, headquartered in Stockholm, with more than €500M under management and 60+ investments to date.

SOURCE Vocca

Thyme Therapeutics launches as a wave of major oncology biologics approaches loss of exclusivity, entering a market where pricing has remained unstable and volatile even as biosimilar competition has grown

NASHVILLE, Tenn., Oct. 8, 2026 — Thyme Companies, a family of businesses purpose-built to solve problems across the cancer care landscape, today announced the launch of Thyme Therapeutics, a new business focused on driving reductions in the cost of oncology drugs. The company will work closely with oncologists, health plans, and manufacturers to commercialize oncology biosimilars. Its model will help patients access more affordable care, make lower-cost treatments easier for oncologists to adopt, and reduce overall healthcare costs.

Biosimilars have already offered promising saving opportunities in cancer care, but unstable prices and other market dynamics have limited those savings. Even when lower-cost options are covered and prescribed, pricing can shift significantly from quarter to quarter, keeping drug spend high and unpredictable. Thyme Therapeutics is built to align incentives across manufacturers, payers, and providers so the savings from lower-cost biosimilars reach patients and hold up over time.

“Few challenges in oncology are more urgent to solve right now than the rising cost of cancer drugs,” said Robin Shah, executive chairman of Thyme Companies. “With Thyme Therapeutics, we have an opportunity to rethink how value moves through the system so that more of the savings created by biosimilars can ultimately benefit patients and the healthcare system as a whole.”

Thyme Therapeutics plans to launch its first asset in 2027 and is actively engaging leading oncology groups, biosimilar manufacturers, and health plans as it builds its initial portfolio. Thyme Therapeutics will build on Thyme Care’s mission to transform cancer care in a way that reduces costs for patients in partnership with both payers and providers as it works to bring additional biosimilars to market.

This launch comes at a critical inflection point for cancer care. U.S. oncology drug spending reached approximately $84 billion in 2025, an increase of roughly 20% in a single year, while several of the industry’s highest-cost cancer therapies are approaching loss of exclusivity. That opportunity could meaningfully reset the economics of cancer care, but only if lower-cost products achieve broad and sustained adoption. Thyme Therapeutics was built to help turn that opportunity into more predictable, durable savings.

Thyme Therapeutics is the first new business launched by Thyme Companies following its formation in September 2026, alongside its Series E financing, and will initially focus on biosimilar medications. Thyme Companies was established to build independent businesses that address distinct challenges across the cancer care ecosystem, with Thyme Therapeutics as the next such business alongside Thyme Companies’ first venture, Thyme Care. To learn more about the company and the team, visit thymetherapeutics.com.

About Thyme Companies
Thyme Companies is the parent of the Thyme family of businesses, focused on building companies against the disconnection in how cancer care is delivered, accessed and paid for. Anchored by Thyme Care, the nationally recognized oncology care company, Thyme Companies develops independent businesses connected by one mission: to transform the experience of cancer for the people living through it. To learn more, visit thymecompanies.com.

About Thyme Therapeutics
Thyme Therapeutics, part of the Thyme family of businesses, is building a new oncology biosimilars model designed to bring lower-cost medicines to market and reduce the cost of cancer via more stable, lower pricing. The company works with leading providers, manufacturers, and health plans to make lower-cost, clinically appropriate cancer treatments easier to adopt. To learn more, visit thymetherapeutics.com.

SOURCE Thyme Companies

DENVER, Oct. 8, 2026 — Pivot Energy, an impact-focused independent power producer of distributed-scale solar and energy storage, today announced the closing of a $173 million term loan facility for a portfolio of 51 community-scale solar projects totaling 135 Megawatts (MWdc) across six states.

Long-time financial partners First Citizens Bank (“First Citizens”), Huntington Bank, and BankUnited provided the takeout financing. The facility refinances the projects from Pivot’s construction warehouse and consolidates Pivot’s first three portfolios under a single term structure, marking the company’s first term loan financing. The transaction also frees up capacity in Pivot’s revolving construction facility to support continued construction of additional projects.

“Closing our first term loan across a consolidated portfolio is an important step for Pivot,” said Bret Labadie, Chief Financial Officer at Pivot Energy. “We’re grateful to First Citizens, Huntington, and BankUnited, who have supported Pivot from the start. This financing gives us the flexibility to grow faster and deliver lasting value where our projects are built, from community investment and agrivoltaics to local jobs and economic development. As the electricity landscape becomes more complex, we’re proud to work alongside utilities, corporate energy buyers, and ratepayers to deliver local, reliable power that strengthens the grid.”

“First Citizens is pleased to continue building on our long-standing relationship with Pivot Energy,” said Mike Lorusso, head of First Citizens Bank’s Energy Finance business. “This financing reflects the strength and diversity of Pivot’s distributed solar portfolio, and we’re proud to support the company through its next stage of growth.”

About Pivot Energy
Founded in 2009, Pivot Energy is a leading national renewable energy provider and independent power producer that develops, owns, and operates solar and energy storage projects. Pivot delivers renewable energy solutions that strengthen local economies, create jobs, and provide affordable, reliable power for businesses and communities across the U.S. As a Certified B Corporation, Pivot combines purpose and performance to ensure every project generates meaningful economic and social value. Pivot is an ECP portfolio company. Learn more at pivotenergy.net.

About First Citizens Bank
First Citizens Bank helps personal, business, commercial and wealth clients build financial strength that lasts. Headquartered in Raleigh, N.C., First Citizens has built a unique legacy of strength, stability and long-term thinking that has spanned generations. First Citizens offers an array of general banking services, including a network of more than 500 branches and offices nationwide; commercial banking expertise delivering best-in-class lending, leasing, and other financial services coast to coast; innovation banking serving businesses at every stage; and a nationwide direct bank. Parent company First Citizens BancShares, Inc. (NASDAQ: FCNCA) is a top 20 U.S. financial institution with more than $200 billion in assets and a member of the Fortune 500™. Discover more at firstcitizens.com.

SOURCE Pivot Energy

EL SEGUNDO, Calif., Oct. 8, 2026 — Gallatin AI, Inc., an AI-native logistics company transforming sustainment decision-making for the U.S. military, today announced $50 million in Series A financing. The round was backed by new and existing investors, including 8VC, Silent Ventures, and others.

“I’m grateful to our early partners across the military logistics community for trusting us with some of the world’s most complex sustainment challenges,” said Woody Glier, Gallatin’s CEO. “This Series A is an important milestone. It gives us the resources to double down on what’s working in the field, accelerate our product roadmap, and scale a capability that builds on the investments in data infrastructure the Pentagon has been making at every echelon. That is how we transform the way joint and allied forces see and sustain themselves. We have the tools and ambition to solve the toughest challenges facing military logistics, and are humbled by the opportunity to keep moving forward.”

Gallatin will use the additional capital to expand its engineering team, accelerate product development, and broaden its suite of AI-enabled sustainment capabilities across the Joint Logistics Enterprise. Navigator, Gallatin’s flagship decision-support platform, connects data and workflows across the force to provide a unified view of readiness while orchestrating critical sustainment processes across vehicle readiness, supply, medical, and other mission-support functions. Navigator is built to transform sustainment decision support from the battlefield to the Pentagon, and is already used by Army and Air Force customers across the tactical, operational, and strategic levels of military planning. Proven in complex fuel, medical, and munitions supply chains, Gallatin’s solutions will expand with the company as it accelerates its permanent presence on four continents.

“Many on our team have lived these sustainment challenges firsthand in uniform, and we know the struggle of not having the information or tools needed to do the job,” said Brian Ballard, the company’s Chief Product Officer. “The opportunity in front of us is bigger than building better software. It is making logistics a source of operational advantage, and giving sustainers the ability to make better decisions before constraints become mission problems.”

Gallatin’s Navigator is currently deployed with U.S. military units around the world, supporting joint and combined exercises from Japan to Alaska to Europe. This funding round follows a successful seed financing in 2024, bringing the total amount raised by Gallatin to $70 million.

About Gallatin

Founded in 2024 and backed by 8VC and leading defense and technology investors, Gallatin AI develops capabilities that make the Joint Logistics Enterprise predictive, visible, and accountable, from the point of production to the point of need. Gallatin is headquartered in El Segundo, California, with offices in Washington, D.C., and Austin, Texas. Its flagship platform, Navigator, is deployed with multiple military units and commercial logistics partners, enabling precision sustainment at the speed of relevance.

For Media Inquiries, please contact Garrett Richards at [email protected]

SOURCE Gallatin AI

71 portfolio organization investments generated $454 million in funding, addressing locally identified needs nationwide

BOSTON, Oct. 8, 2026 — National nonprofit GreenLight Fund’s 2025-2026 Impact Report shows its investments reached 1.6 million individuals and families this past year, generating progress across essential needs, education, career development and financial resiliency.

From July 2025 through June 2026, GreenLight expanded to Dallas, its 15^th city, and grew its national portfolio to 71 investments, bringing proven programs into new communities to address locally identified needs.

“This report demonstrates what is possible when we listen to communities, invest in solutions with a track record of results and provide the support needed to help those programs take root and grow,” said GreenLight Fund CEO Ali Knight. “Reaching 1.6 million individuals and families is an important milestone, and what matters most is the measurable change children and families are experiencing in communities across our network.”

GreenLight’s $47.8 million investment in its portfolio organizations helped unlock more than $454 million in follow-on funding–nearly ten dollars for every dollar GreenLight Fund invested.

GreenLight works alongside residents and local leaders to identify needs, then finds evidence-based nonprofit programs to address them and helps launch those solutions with multiyear funding and support.

Some results highlighted in the report:

• In Cincinnati, 100% of households participating in HomeStart’s Renew Collaborative retained housing.
• Across Greater Newark, the Twin Cities and the Bay Area, Food Connect distributed more than 2.3 million meals.
• In Baltimore, 1,400 ParentChild+ home visits helped prepare 100% of participating families for their children’s academic success. 
• The Bay Area’s Blueprint Schools reached 1,642 students, with 89% reporting increased confidence in math. 
• Across six cities, workforce development program participants earned wages 2-3x higher the local minimum wage.
• In Newark, 77% of EMS Corps graduates obtained full-time employment.
• Detroit’s RxKids distributed $10.7 million to support 4,195 families during pregnancy and their first year postpartum.
• Philadelphia’s Compass Working Capital participants graduated with average escrow savings of $9,861. 

“These results and more are possible because local expertise and comprehensive due diligence drive every GreenLight investment,” said GreenLight Fund Co-Founder and Board Chair John Simon. “As we continue growing our national network, we remain focused on listening to communities, investing in solutions with demonstrated results and providing on-the-ground support for long-term sustainability.”

Learn more about GreenLight Fund’s impact: greenlightfund.org/report/our-impact/.

CONTACT: [email protected] 

SOURCE GreenLight Fund

Versapay extends AI that’s been earning trust in cash application for years — now built into collections, payments, and ERP connectivity

SAN FRANCISCO, Oct. 8, 2026 — Versapay, a leading platform for business payments and accounts receivable automation, today announced Versapay Intelligence, an expanded AI layer running across its platform, alongside new capabilities within its core accounts receivable platform and deeper ERP-embedded integrations. Together, the updates extend Versapay’s coverage across invoicing, collections, cash application, payments, and ERP connectivity, reinforcing the company’s position at the center of the invoice-to-cash workflow.

AI is not new to Versapay’s platform. The company has applied AI and machine learning within cash application for years — powering remittance matching and machine-learning-based risk segmentation well before AI became a standard feature in invoice-to-cash software. Today’s announcement expands that investment, unifying it into one intelligence layer that runs across the platform rather than a single module. 

“Versapay is applying one intelligence layer across a platform that already unifies invoicing, collections, cash application, payments, and ERP connectivity,” said Carey Kolaja, Chief Executive Officer of Versapay. “That’s our edge: we’ve spent more than 20 years moving invoices and money, so we see the full picture — not just a transaction, but the operational, payment, and relationship signals behind it. That’s what lets us help define where invoice-to-cash is headed, instead of just keeping pace with it.”

Versapay Intelligence: Earning Trust in Stages

Versapay Intelligence is built around a simple premise: AI is only as valuable as it is trusted, and trust is earned incrementally. Rather than introducing autonomous AI as a headline feature, Versapay designed a four-stage framework that gives customers control over how much responsibility AI takes on, and when:

• Augment — AI supports workflows, surfaces signals, and eliminates manual research, while the customer makes the final call.
• Assist — AI shapes outcomes, drafts communications, orders queues, and flags risks, while the customer acts from a position of clarity.
• Action — AI executes across systems within configured boundaries the customer sets.
• Autonomous — AI coordinates with other agents and closes loops within permission structures the customer has granted.

Within this framework, three Versapay Intelligence capabilities are live: a Versapay Assistant that answers questions like which invoices to focus on today, real-time sentiment scoring that flags at-risk customer conversations, and AI-generated customer summaries covering payment history, overdue balance, credits, and oldest open invoice. Versapay is also now in beta with AI augmented Cash Application, reading remittance details across PDFs, spreadsheets, and scanned images — in dozens of formats — and matching them to open invoices automatically, greatly improving match rates and predictability, with more capabilities on the way.

“We wanted to use AI to augment our customers’ judgment and take work out of the equation,” said Christy Johnson, Chief Product Officer of Versapay.  That’s why we started with an assistant that answers your questions directly and surfaces the buyer signals that could have been missed, an enhanced AI in Cash Application that shows its work. When AI tells you the insight and explains how it got there, it earns the trust to take on more.”

Expanding Collections Within Versapay’s Core AR Platform

Versapay customers wanted more out of collections capabilities: less manual work and the freedom to build their own strategies. Collections, and connecting customers with their buyers transparently, have always been a core differentiator of the platform. Now Versapay is reaching further leveraging the intelligence above by offering: automatic segmentation by risk and behavior, configurable workflows with tailored outreach cadences, and auto-prioritized task lists that put the highest-priority accounts in front of collectors first. A unified communications log and performance dashboards for DSO, aging, and promise-to-pay complete the picture. 

“We were already running our core AR with Versapay, so expanding into Versapay’s new Collections module felt like a natural next step rather than starting over with a new system,” shared Lisa Pillans, Corporate Controller, Essential Cabinetry Group. We’re most excited about smarter segmentation and automation of routine reminder emails, and getting a daily task list that tells our collector exactly who to follow up with and why — including payment promises — so she can spend her time on the accounts that truly need attention.”

Meeting Customers Inside the Systems They Already Run

Customers asked for one more thing: to be met where they already work, inside the systems they run every day. Versapay continues to embed that intelligence directly into those workflows — across ERPs and other financial systems, including NetSuite, Sage Intacct, and Microsoft Dynamics — so teams can put insights into action as they manage invoices, collections, and cash application. Based on feedback these expanded features have just released:

• Embedded payments for Microsoft Dynamics F&SCM
• Expanded NetSuite Pay, with Canadian merchant support 
• Aggregated payment through grouped invoices through Versapay’s customer portal that sync directly back to NetSuite
• Project-based and multi-currency invoice support for Sage Intacct

Versapay has also been recognized by G2 with “Users Love Us” and “Leader” badges.

About Versapay

Versapay is the platform that rewires AR by removing barriers from collecting and reconciling B2B payments, providing end-to-end cash flow clarity so businesses can manage working capital on their terms. By connecting finance teams, their business systems, customers, and payment activity into a single intelligent ecosystem, Versapay turns money matters into a data-driven advantage. With 10,000 customers and 5M+ companies transacting, Versapay facilitates 120M+ transactions and processes $300B+ in payments volume annually. To learn more about how Versapay eliminates financial friction, visit versapay.com.

SOURCE Versapay

Glilot Capital and Sienna Venture Capital Co-Lead Series A Round, Bringing Total Funding Secured to Date to $35 Million

NEW YORK and TEL AVIV, Israel, Oct. 8, 2026 — Rein Security, the AI-native runtime security platform for enterprises, today announced that the company has raised $25 million in Series A financing, bringing the company’s total funding to $35 million. The round was co-led by Glilot Capital and Sienna Venture Capital, with participation from Corner Ventures, Atlacle and RNP Capital Advisors.

The funding comes as enterprises rapidly deploy AI agents with increasingly broad access to business systems, data and workflows, creating a new class of security risks that traditional approaches were not designed to detect or stop. According to Gartner, the market for securing AI is projected to reach nearly $4.8 billion in 2027, up 68.7% from 2026, and nearly $7.7 billion by 2028. As AI agent adoption accelerates and agents become increasingly autonomous, enterprises face two security challenges at once, securing the agents they build while defending against increasingly capable AI-driven attacks.

Rein addresses both sides of this challenge. Its platform is built on patented sidecar technology that operates at runtime, at the point where agents execute actions. This gives security teams visibility into every line of code an agent runs and every resource it touches, along with governance over agent activity and real-time guardrails that block harmful actions. Rein also secures the agent supply chain, all without routing company or customer data through a gateway or proxy.

“Enterprise AI agents are becoming essential to how businesses operate, but security hasn’t kept pace with the autonomy these systems now have,” said Matan Bar-Efrat, co-founder and CEO of Rein Security. “This funding enables us to keep building the infrastructure enterprises need to deploy AI agents with visibility, control and confidence.”

Enterprises are adopting AI agents faster than they can secure them, and most of the risk these agents create is both new and hidden. It sits in the downstream actions they take automatically across business systems, often on instructions passed along by another system or agent rather than a person. Securing agents means understanding every action they take and stopping harmful ones. The same is true of adversarial AI, which attacks at machine speed and can overwhelm security teams. This calls for a completely different strategy: shifting focus away from posture and vulnerability management to a more proactive approach that prioritizes prevention and protection. 

“The agent economy is upon us, and the rapid adoption of AI agents is creating a fundamental shift in enterprise security,” said Arik Kleinstein at Glilot Capital. “As agents gain the ability to access systems, make decisions and act autonomously, enterprises need a new approach built specifically for this new landscape. This is a fast-moving and underserved area of security, and Rein has the platform, vision and early traction to help define it.”

The risks Rein uncovers are already appearing in production environments. For example, at Black Hat USA 2026, Rein’s vulnerability research team, Agent Breakers, presented research showing how it compromised the AI shopping agent of a top-five U.S. retailer. The work showed how quickly AI adoption is outpacing security. Furthermore, a global enterprise’s onboarding agent opened what looked like an ordinary PDF. Hidden inside was a prompt injection that directed the agent to act outside its intended role. Rein detected and blocked the action before any damage was done.

“As an enterprise’s technology ecosystem grows and evolves to include more AI agents that have a direct impact in production environments, security becomes an even greater concern. The frameworks that exist today are simply not equipped to handle this transition,” said Thomas Visan at Sienna Venture Capital. “Rein’s differentiated platform explicitly addresses current, as well as new, agentic AI security threats, giving the company a distinct position in this rapidly evolving market.”

Answering the Call for Stronger Agentic AI Protection 

Amid a period of significant revenue and customer growth, Rein will use the new capital to accelerate product innovation, advance agentic research and support global hiring. Since its January 2026 launch, Rein has increased revenue by 8x and grown its customer base by 5x.

New customers, including Flex and Swimlane, broaden Rein’s reach across industries including financial services, healthcare, SaaS, data, retail and energy.

As enterprises build and deploy increasingly capable AI agents, Rein is seeing growing demand for security that can keep pace with agent adoption. The company’s platform is already securing thousands of AI agents that execute millions of actions, including Dun & Bradstreet and digital-first insurance leader, Lemonade. Rein protects AI agents for Lemonade, supporting services used by over three million active customers; as well as agents for Dun & Bradstreet, powering agentic products used by more than 240,000 customers.

“Our customers rely on Dun & Bradstreet for trusted data, and that trust has to extend to every AI agent we put into production,” said Jay DePaul, chief cybersecurity & technology risk officer at Dun & Bradstreet. “Rein helps us see and control what our agents do at scale, so we can keep innovating with agentic AI while protecting the customers who depend on it.”

Rein has also earned recognition from the broader technology and cybersecurity community in recent months. The company was selected as one of eight early-stage companies to compete in the AI Conference’s Start Up Showdown and was named to TechCrunch’s Startup Battlefield 200 as one of the most promising early-stage startups in the cybersecurity category.

For more information, visit www.reinsec.io.

About Rein Security:
Rein Security is the agentic AI security company purpose-built for enterprise agents. With a patented, real-time architecture, Rein delivers full visibility and protection across every enterprise agent – tracing every action to the line of code that triggered it and connecting it to its business outcome. Trusted by leading Fortune 500 companies and backed by Glilot Capital, Sienna Venture Capital, and Corner Ventures, Rein Security was founded in 2024 and is co-headquartered in New York City and Tel Aviv.

Media Contact:
Bateman Agency for Rein Security
[email protected] 

SOURCE Rein Security, Inc.

F-Prime leads financing, with participation from A1 Health Ventures and .406 Ventures, to help AblePay reach more health systems and patients nationwide

ALLENTOWN, Pa., Oct. 7, 2026 — AblePay Health (“AblePay”), a healthcare affordability company focused on helping patients better manage out-of-pocket medical costs while improving payment performance for providers, today announced the completion of a $20 million Series A financing led by F-Prime, with participation from A1 Health Ventures and .406 Ventures.

The investment will support AblePay’s continued growth, deepen its technology platform, and expand the company’s services for both patients and providers as it positions itself at the forefront of solving healthcare’s affordability challenges.

According to the Centers for Medicare & Medicaid Services, Americans paid $591 billion out of pocket for healthcare in 2025, an increase of 6% from the prior year. For patients, rising costs can make an already complicated healthcare experience even harder to manage. For providers, more of the revenue they have earned depends on the patient’s ability and willingness to pay, making the financial experience increasingly important to both the patient relationship and revenue cycle performance.

“Healthcare affordability affects both sides of the bill,” said John Fistner, Founder and CEO of AblePay Health. “Patients need a better way to manage the cost of care, and providers need a better way to collect the revenue they have already earned. AblePay was designed to address those needs and ten years later, that is what still drives us.

Today, only a fraction of that burden is served by any third-party financing solution, leaving millions of patients and the health systems that treat them, exposed to an escalating, largely unaddressed problem. This investment gives us the opportunity to reach more health systems, help more patients, and continue building on a model that works for both.”

Using a proprietary technology-enabled platform, AblePay uniquely and seamlessly integrates with healthcare providers to guarantee non-recourse payment on an accelerated, predictable timeline. Enrolled patients receive flexible payment options with the opportunity to save on their out-of-pocket responsibility with free access to AblePay’s Advocacy Team to assist with billing questions or issues.

AblePay is redefining what a modern, technology-driven approach to patient financial engagement can look like.

“AblePay has built a differentiated model that addresses a significant market pain point for both healthcare providers and patients,” said Nikhil Marathe, Principal at F-Prime. “The company combines a compelling patient value proposition with meaningful financial and operational benefits for healthcare organizations. We are excited to partner with John and the AblePay team alongside A1 Health Ventures and .406 Ventures as the company enters its next stage of growth.”

The investment comes as AblePay enters its second decade of growth. The additional capital will help the company expand its reach, strengthen its capabilities, and continue developing solutions that make the healthcare payment experience simpler and more affordable for patients while delivering stronger financial outcomes for providers.

About AblePay Health

AblePay Health is a healthcare affordability and patient engagement company dedicated to helping patients save on out-of-pocket medical expenses while supporting health systems and providers with improved revenue performance and higher patient satisfaction. Founded in 2016, AblePay partners with healthcare organizations to simplify the payment experience while addressing the affordability challenges facing both patients and providers.

Learn more at ablepayhealth.com.

About F-Prime

F-Prime is a leading global venture capital firm that creates and invests in healthcare and technology companies, partnering with entrepreneurs to build groundbreaking businesses. For more than 50 years, the firm has invested across therapeutics, medtech, healthtech / services and technology, helping turn innovative ideas into transformative companies and products. F-Prime combines capital with the insight, domain expertise and relationships of its investors, engineers, operators, doctors and scientists to help its companies navigate complex challenges and make a transformative impact.

Learn more at fprimecapital.com.

About A1 Health Ventures

A1 Health Ventures is a Chicago-based venture capital firm investing in healthcare technology and technology-enabled services businesses that solve the healthcare industry’s most pressing challenges. Backed by health system LPs operating 110+ hospitals & serving over 15M patients annually, A1 leverages deep healthcare expertise and an expansive provider network to help its companies accelerate adoption and drive meaningful real-world impact.

Learn more at a1healthventures.com.

About .406 Ventures

.406 Ventures is a Boston-based venture capital firm with over $1.3B under management and two decades of experience leading or co-leading early-stage investments in pioneering healthcare, data + AI, and cybersecurity companies founded by visionary entrepreneurs.

Learn more at 406ventures.com.

SOURCE Ablepay Health, LLC